Key result
PCSK9 inhibitors cut MACE across broad populations, including patients with ASCVD and diabetes.
PCSK9 inhibitors are an effective and safe class of LDL-lowering therapies that reduce major adverse cardiovascular outcomes in high-risk patients.
On the basis of seminal genetic discoveries, proprotein convertase subtilisin/kexin Type 9 (PCSK9) inhibitors were developed as a new class of LDL cholesterol-lowering drug, with a potency on par with and on top of high-intensity statins and an excellent safety profile. A series of large cardiovascular outcomes trials have now established the ability of monoclonal antibody PCSK9 inhibitors to reduce the risk of major adverse cardiovascular outcomes across a broad range of patients, including those with a prior major atherosclerotic cardiovascular disease (ASCVD) event, those with atherosclerosis but without a prior major ASCVD event, and those with diabetes. Moreover, these trials have shown the clinical benefit of lowering LDL cholesterol to ∼1 mmol/L (∼40 mg/dL) in such patients. New members of this class are being studied including oral inhibitors, RNA interference, and gene therapy.
No takes yet. Share an insight, caveat, or question.
Sabatine et al. (2026) conducted a review in Atherosclerotic cardiovascular disease (ASCVD) and diabetes. PCSK9 inhibitors was evaluated on Major adverse cardiovascular outcomes. PCSK9 inhibitors reduce the risk of major adverse cardiovascular outcomes across a broad range of patients, including those with prior ASCVD, atherosclerosis without prior ASCVD, and diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: